Skip to main content
AMCP 2025 Main banner
Back

Drugs, Diseases, and the Managed Care Impact

(D2) Advancing Equitable Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) Management Strategies in Managed Care

Tuesday, April 1, 2025
1:30 PM – 2:45 PM CST
Location: 320
CPE
ACPE UAN:0233-0000-25-008-L01-P | Contact Hours: 1.25 | Activity Type: Knowledge-based
This activity is supported by an independent medical education grant from BridgeBio Pharma, Inc.

Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM) is a rare and progressive disease characterized by the misfolding of amyloid fibrils that aggregate and deposit locally in one specific area of the body or deposit systemically, affecting many tissues and organs. Although a rare disease, the estimated prevalence in the United States (U.S.) is 120,000 and growing as we better understand its clinical presentation and appropriate diagnostic methods. However, in the U.S., significant diagnostic gaps are evident among Black and Hispanic/Latinx communities with ATTR-CM.

As experts in all aspects of drug therapy, managed care pharmacists play a pivotal role in shaping patient outcomes, access to treatments, and drug utilization by leveraging evidence-based recommendations to design and implement pharmacy and drug-related medical benefits. This is especially necessary for rare diseases, like ATTR-CM, to optimize clinical and quality programs that meet patient care needs while simultaneously managing the economic burden and complexities of the health care system.

This session will dive into the key data from clinical trials for novel ATTR-CM treatments, the complexities of health disparities that affect this disease and key managed care considerations.

Learning Objectives:

At the completion of this activity, participants should be able to:
  1. Recognize the clinical indicators for early screening and diagnosis of Transthyretin Cardiac Amyloidosis (ATTR-CM), particularly among a diverse population
  2. Identify the burden of health disparities in ATTR-CM disease management on health outcomes and access to care in the United States.
  3. Distinguish the clinical efficacy, safety, monitoring, and patient selection criteria for new and emerging disease-modifying treatment options for ATTR-CM
  4. Discuss managed care approaches to optimizing diagnosis and the referral process, health outcomes, and equitable access to care for managing ATTR-CM.